- The disease
- Severe burns damage the skin's full thickness, destroying the dermis (the structural layer beneath the outer skin) and leaving the body unable to regenerate tissue on its own. These wounds require surgical reconstruction, typically using skin grafts taken from the patient's own body (autograft). When burns are extensive, there may not be enough healthy donor skin available, and the risk of infection, scarring, and functional impairment is high. Globally, burns are a leading cause of trauma-related morbidity, particularly in low-to-middle-income countries, though they affect patients of all ages and geographies.
- What the asset is trying to do
- NovoSorb BTM (Biodegradable Temporising Matrix) is a synthetic polymer scaffold manufactured by PolyNovo that is placed over a wound to act as a temporary dermal substitute. The device is designed to allow the body's own cells to infiltrate and populate the scaffold over time, forming a new dermal layer before a thin skin graft is applied on top. Unlike biological dermal substitutes derived from animal or human tissue, NovoSorb BTM is fully synthetic, which removes the variability associated with donor-derived materials. The polymer is designed to biodegrade as new tissue forms, leaving behind the patient's own regenerated dermis.
- What the trial is measuring, and why it matters
- The lead registered trial (NCT04090424) is assessing the safety and effectiveness of NovoSorb BTM in severe burns against standard of care (per ClinicalTrials.gov NCT04090424). Primary completion was listed as 2026-05-30 and the trial status is active, not recruiting, with a target enrolment of 150 patients (per ClinicalTrials.gov NCT04090424). Specific primary and secondary endpoints are not detailed in the input data provided; further detail is available on the ClinicalTrials.gov record.
- Efficacy benchmarks in this setting
- Published benchmarks for dermal substitutes in severe burns include data on Integra Dermal Regeneration Template, which has been studied in full-thickness burns; reported outcomes in the literature include wound closure rates and graft take, though direct figures vary by study design, patient population, and burn severity, and no single universally accepted benchmark figure is available from the sources provided here. Readers should consult the peer-reviewed burns literature and product prescribing information for specific comparator figures. Any early-stage or interim figures from this NovoSorb BTM study are not statistically comparable to results from approved products studied in different populations under different protocols.
- Commercial context
- NovoSorb BTM has received regulatory clearance or approval in multiple markets including the United States, Australia, and the European Union, and is therefore a commercial product rather than an investigational asset (per PolyNovo public disclosures). The registered trial (NCT04090424) is a post-market study, not a pivotal approval trial. The burns and complex wound care market includes other approved dermal substitutes; specific market size figures and disclosed deal comparables are not available in the input data provided. NovoSorb BTM is PolyNovo's lead commercial product based on public company disclosures.